Status:
COMPLETED
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
Lead Sponsor:
Cocrystal Pharma, Inc.
Collaborating Sponsors:
hVIVO Services Limited
Conditions:
Influenza A
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
Participants in this study will be given either CC-42344 (one of two dose levels) or placebo orally for 5 days after receiving an influenza (flu) challenge virus. Participants will not know whether th...
Detailed Description
This is a single-center, phase 2a, randomized, double-blind, placebo-controlled study in healthy adult participants. The primary goal of this study is to assess the antiviral activity of orally admini...
Eligibility Criteria
Inclusion
- Healthy adults
- Body weight ≥50 kg
- Body mass index ≥18 kg/m2 and ≤35 kg/m2
- Serology results consistent with susceptibility to challenge virus infection
Exclusion
- History of or current significant medical condition
- Upper or lower respiratory tract infection within 4 weeks
- Vaccination within 4 weeks
Key Trial Info
Start Date :
November 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 18 2024
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT06160531
Start Date
November 25 2023
End Date
July 18 2024
Last Update
August 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary BioEnterprises Innovation Centre
London, United Kingdom, E1 2AX